#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neurofibromatosis Allogenic stem cell transplantation Chondrosarcoma metastatic Glycogen storage disease type V Adenocarcinoma gastric Phaeochromocytoma Plasma cell myeloma refractory Blastic plasmacytoid dendritic cell neoplasia Plasma cell myeloma Erythema Oesophageal squamous cell carcinoma stage II Nasopharyngeal cancer Marginal zone lymphoma recurrent PIK3CA related overgrowth spectrum Synovial sarcoma More trials…

    Learn about Rare Diseases

    Angiosarcoma metastatic – Basic Information Leiomyosarcoma recurrent – Basic Information Combined immunodeficiency Pleomorphic leiomyosarcoma – Basic Information Mucopolysaccharidosis II – Basic Information Brain stem glioma – Treatment Chondrosarcoma Mucopolysaccharidosis III – Life with Disease Paroxysmal nocturnal haemoglobinuria – Trials in Disease Progressive supranuclear palsy – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VERCIRNON Sirexatamab Mrna-4157 7-Ethyl-10-Hydroxycamptothecin CITRIC ACID ANHYDROUS Allopurinol Sodium Rosuvastatin Atacicept Acetylcysteine PRT3789 Mercaptopurine Monohydrate Loperamide Hydrochloride Fluconazole Imidapril Hydrochloride Rosuvastatin Calcium Esketamine Dnth103 GRNA-001 Rbl005.3 FOSMANOGEPIX More therapies…

    Learn about Your Condition

    Hairy cell leukaemia Depression Food allergy Acute kidney injury Mesothelioma Pulmonary alveolar haemorrhage Pruritus Malignant fibrous histiocytoma Renal failure Dent's disease Intestinal ischaemia Fibromyalgia Sleep disorder Brain cancer metastatic Metabolic syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Cliniques Universitaires Saint-Luc

Cliniques Universitaires Saint-Luc

Hippokrateslaan 10, Batiment 54, Woluwe-Saint-Lambert, 1200, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

    Recruiting

    3 1
    Investigated Drugs:
    • Elafibranor
    Austria Belgium Czechia Denmark Finland France +9

  • A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST SEZ6, CONJUGATED TO (2S)-2-(2-BROMOACETAMIDO)-N-[(2S)-1-({3-[(7S)-7-ETHYL-7-HYDROXY-8,11-DIOXO-7,8,11,13-TETRAHYDRO-2H,10H-[1,3]DIOXOLO[4,5-G]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-14-YL]BICYCLO[1.1.1]PENTAN-1-YL}AMINO)-1-OXOPROPAN-2-YL]-3-METHYLBUTANAMIDE
    • Topotecan
    Austria Belgium France Germany Greece Italy +1

  • Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

    Recruiting

    3 1
    Investigated Drugs:
    • ADX-324
    Austria Belgium Bulgaria Croatia Czechia France +5

  • A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Investigated Diseases:
    • Metabolic dysfunction-associated steatohepatitis
    Austria Belgium Bulgaria France Germany Greece +4

  • Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Austria Belgium Bulgaria France Germany Greece +4

  • Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Central nervous system lymphoma
    Investigated Drugs:
    • Rituximab
    • Temozolomide
    Austria Belgium Czechia France Germany Hungary +3

  • VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • VMX-C001
    Austria Belgium Bulgaria Czechia Estonia France +9

  • Long-Term Safety Study of Zigakibart in Adults with IgA Nephropathy Who Have Completed Previous Zigakibart Trials

    Recruiting

    3 1 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • ZIGAKIBART
    Belgium Croatia Czechia France Germany Greece +2

  • Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • K-ras gene mutation
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Divarasib
    • Budesonide
    • Carboplatin
    Belgium Denmark France Germany Greece Hungary +6

  • A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Barzolvolimab
    • Epinephrine
    Belgium Bulgaria Croatia Czechia Denmark France +10
Previous Page
1 … 24 25 26 27 28 … 67
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!